for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Roche Holding Ltd.

ROG.S

Latest Trade

282.90CHF

Change

-2.15(-0.75%)

Volume

1,625,980

Today's Range

282.05

 - 

284.65

52 Week Range

229.20

 - 

285.35

As of on the Virt-X ∙ Minimum 15 minute delay

Pricing

Previous Close
285.05
Open
282.55
Volume
1,625,980
3M AVG Volume
36.75
Today's High
284.65
Today's Low
282.05
52 Week High
285.35
52 Week Low
229.20
Shares Out (MIL)
856.06
Market Cap (MIL)
245,513.50
Forward P/E
14.86
Dividend (Yield %)
2.91

Next Event

Roche Holding AG at Bloomberg Future of Finance

Latest Developments

More

FDA Approves Roche's Cobas Babesia Blood Test

Roche Receives FDA Clearance For Cobas Pro Integrated Solutions

Roche: Update On Genentech’s Breast Cancer Therapy

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Roche Holding Ltd.

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.

Industry

Major Drugs

Contact Info

Grenzacherstr. 124

+41.9.732354295

http://www.roche.com

Executive Leadership

Severin Schwan

Chairman of the Corporate Executive Committee, Chief Executive Officer, Executive Director

Christoph Franz

Non-Executive Independent Chairman of the Board

Fritz Gerber

Honorary Chairman of the Board

Andre S. Hoffmann

Non-Executive Independent Vice Chairman of the Board

Alan Hippe

Member of the Corporate Executive Committee, Chief Financial Officer, Information Technology Officer

Key Stats

2.36 mean rating - 25 analysts
Sell
Hold
Buy
Revenue (MM, CHF)

2016

50.6K

2017

53.3K

2018

56.8K

2019(E)

61.3K
EPS (CHF)

2016

14.530

2017

15.340

2018

18.580

2019(E)

19.220
Price To Earnings (TTM)
20.88
Price To Sales (TTM)
4.15
Price To Book (MRQ)
8.70
Price To Cash Flow (TTM)
15.23
Total Debt To Equity (MRQ)
69.75
LT Debt To Equity (MRQ)
54.88
Return on Investment (TTM)
23.03
Return on Equity (TTM)
15.43

Latest News

BRIEF-Roche Company Chugai Says Obtained Approval For Additional Indication And Formulation For Tecentriq In Pd-L1-Positive Triple Negative Breast Cancer In Japan

* COMPANY CHUGAI SAYS OBTAINED APPROVAL FOR ADDITIONAL INDICATION AND FORMULATION FOR TECENTRIQ IN PD-L1-POSITIVE TRIPLE NEGATIVE BREAST CANCER IN JAPAN Source text for Eikon: Further company coverage:

BRIEF-Roche Holding Reports Analysis Of Ocrevus Phase IIIb Study

* POST-HOC ANALYSIS FROM A PHASE III OPEN-LABEL EXTENSION STUDY SHOWED A 42 PERCENT REDUCTION IN RISK OF PPMS PATIENTS NEEDING A WHEELCHAIR AFTER 6.5 YEARS OF OCREVUS TREATMENT COMPARED WITH PATIENTS WHO STARTED OCREVUS AFTER DOUBLE-BLIND PERIOD

Roche, Spark again extend $4.3 billion takeover offer

Roche Holding <ROG.S> and Spark Therapeutics <ONCE.O> announced on Tuesday another extension of the Swiss drugmaker's $4.3 billion takeover offer for the U.S. gene therapy specialist as regulatory reviews continue.

BRIEF-Roche Presents Positive Study Results For One-Dose Xofluza In Children With Flu

* ROCHE PRESENTS POSITIVE PHASE III STUDY RESULTS FOR ONE-DOSE XOFLUZA IN CHILDREN WITH FLU

BRIEF-Enable Injections Enters Into Partnership With Genentech

* ENABLE INJECTIONS ENTERS INTO STRATEGIC PARTNERSHIP WITH GENENTECH, A MEMBER OF THE ROCHE GROUP

Roche taps Lilly executive Garraway as chief medical officer

Swiss drugmaker Roche Holding on Monday named Eli Lilly executive Levi Garraway to succeed Sandra Horning as chief medical officer and head of global product development.

Roche taps Eli Lilly executive as chief medical officer

Swiss drugmaker Roche Holding on Monday named Eli Lilly executive Levi Garraway to succeed Sandra Horning as chief medical officer and head of global product development.

Roche cancer treatment priced at $17,050 a month, lower than rival Vitrakvi

Roche Holding AG has priced its personalized cancer treatment, Rozlytrek, at about $17,050 per month, nearly half of the monthly price of a rival drug from Bayer AG and Eli Lilly and Co that was approved last year.

Roche prices personalized cancer treatment at about $204,560 annually

Roche Holding AG priced at about $204,560 a year its personalized cancer treatment, Rozlytrek, which targets tumors with specific genetic mutations, the Swiss drugmaker said.

BRIEF-Roche Announces Monthly and Yearly Rozlytrek Treatment Costs In U.S.

* ROCHE - MONTHLY COST OF ROZLYTREK FOR ADULTS WITH ROS1-POSITIVE METASTATIC NSCLC & FOR ADULTS WITH NTRK FUSION-POSITIVE SOLID TUMOURS IS ABOUT $17,050

BRIEF-Roche Wins U.S. FDA Approval For Rozlytrek Cancer Treatment

* FDA APPROVES ROCHE’S ROZLYTREKTM (ENTRECTINIB) FOR PEOPLE WITH ROS1-POSITIVE, METASTATIC NON-SMALL CELL LUNG CANCER AND NTRK GENE FUSION-POSITIVE SOLID TUMOURS

Roche's personalized cancer treatment wins FDA approval

The U.S. Food and Drug Administration approved Roche Holding AG's personalized cancer treatment, which targets tumors with specific genetic mutations, irrespective of where in the body the disease started, the agency said on Thursday.

Roche's personalized cancer treatment wins FDA approval

The U.S. Food and Drug Administration approved Roche Holding AG's personalized cancer treatment, the agency said on Thursday.

BRIEF-Health Canada Approves Tecentriq In Combination With Carboplatin & Etoposide

* HEALTH CANADA APPROVES TECENTRIQ® (ATEZOLIZUMAB), FIRST NEW TREATMENT IN 20 YEARS FOR AGGRESSIVE FORM OF LUNG CANCER(1)

Roche loses another bid to halt Amgen sales of biosimilar cancer drug

A federal appeals court on Wednesday denied a request by Roche Holdings subsidiary Genentech Inc for a temporary order keeping a biosimilar version of its cancer drug Herceptin marketed by Amgen Inc off the U.S. market.

Roche says test showed Tecentriq helped vs bladder cancer

Roche Holding said its Tecentriq drug combined with platinum-based chemotherapy reduced the risk of the disease worsening or death in patients with advanced bladder cancer, the Swiss pharma company said on Monday.

Roche says test showed Tecentriq helped bladder cancer

Roche Holding said its Tecentriq drug combined with platinum-based chemotherapy reduced the risk of the disease worsening or death in patients with advanced bladder cancer, the Swiss pharma company said on Monday.

BRIEF-Roche CEO says committed to Spark deal, portfolio "without any question"

* CEO SAYS VERY CONFIDENT WILL CLOSE SPARK TRANSACTION BY END OF 2019, CANNOT COMMENT ON ONGOING FTC REVIEW

Roche takes fight against Amgen’s biosimilars for Avastin, Herceptin to Fed Circuit

Roche Holdings subsidiary Genentech Inc has asked a federal appeals court to keep biosimilar versions of its cancer-fighting blockbusters Avastin and Herceptin off the U.S. market, after Amgen announced it had started selling the copies last week.

BRIEF-Roche Expands Global Access Programme Beyond HIV

* ROCHE EXPANDS GLOBAL ACCESS PROGRAM BEYOND HIV TO ALSO INCLUDE DIAGNOSTIC TESTS FOR TUBERCULOSIS, HEPATITIS, AND HUMAN PAPILLOMAVIRUS Source text for Eikon: Further company coverage: (Reporting by Berlin Speed Desk)

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up